TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06099990: A Multicenter, Randomized, Double-blind Phase Ib/III Clinical Study of Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Trea

Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 660 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06099990 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06099990 Rescue Dossier →